Advancing Next-Generation ADCs: Clinical Insights from the GlycoConnect® Platform & Expansion of Lonza’s toxSYN® Platform

Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Advancing Next-Generation ADCs: Clinical Insights from the GlycoConnect® Platform & Expansion of Lonza’s toxSYN® Platform

12:30 pm - Tuesday 13th October 2026

Discovering how Lonza’s GlycoConnect®, HydraSpace®, and toxSYN® technologies are shaping differentiated ADCs designed to enable improved therapeutic index

Getting an inside look at a pipeline of 30+ GlycoConnect® ADCs, including clinical insights from advanced partner programs

Exploring the future of targeted therapies dual payload toxSYN® classes to protein-protein conjugates with enhanced BBB transport

Speakers:

Anette Sommer

Head of Biochemistry

Lonza

Advancing Next-Generation ADCs: Clinical Insights from the GlycoConnect® Platform & Expansion of Lonza’s toxSYN® Platform

Advancing Next-Generation ADCs: Clinical Insights from the GlycoConnect® Platform & Expansion of Lonza’s toxSYN® Platform

Speakers:

Venue

Map

Contact

Join Our Team

About Us

Explore Our Conferences

Stay Connected

Search

Organized By